CRSP vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

CRSP

53.0
AI Score
VS
It's a Tie!

DNA

53.0
AI Score

Investment Advisor Scores

CRSP

53score
Recommendation
HOLD

DNA

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CRSP DNA Winner
Revenue 11.64M 19.47M DNA
Net Income -214.09M -82.59M DNA
Net Margin -1839.4% -424.1% DNA
Operating Income -247.52M -71.37M DNA
ROE -12.3% -18.6% CRSP
ROA -8.1% -8.0% DNA
Total Assets 2.65B 1.03B CRSP
Cash 291.34M 143.86M CRSP
Current Ratio 17.85 5.15 CRSP
Free Cash Flow -193.55M -48.62M DNA

Relative Price Performance (Last 90 Days)

CRSP 1M: -17.3% · 3M: -3.8% DNA 1M: -14.3% · 3M: -8.1%

Current Technical Phase

CRSP

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 48.0 · Price: $49.68

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 56.1 · Price: $8.91

Fundamentals Snapshot

Metric CRSP DNA
Market Cap
Forward P/E -12.8 -2.8
Trailing P/E
Revenue (TTM)
Revenue Growth 0.7% -0.5%
Gross Margin -116.7% 0.7%
Operating Margin -89.3% -3.7%
EPS -6.17 -5.38
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CRSP and DNA are evenly matched, both winning 4 key financial metrics each. This is a close call that depends on your specific investment goals.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.